Get the Stockscreener App
32.80
1.83%
-0.61
Pharvaris Nv stock is traded at $32.80, with a volume of 182.17K.
It is down -1.83% in the last 24 hours and up +13.85% over the past month.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
See More
Previous Close:
$33.41
Open:
$33.56
24h Volume:
182.17K
Relative Volume:
0.59
Market Cap:
$2.29B
Revenue:
-
Net Income/Loss:
$-195.21M
P/E Ratio:
-10.33
EPS:
-3.1763
Net Cash Flow:
$-176.19M
1W Performance:
+1.86%
1M Performance:
+13.85%
6M Performance:
+36.55%
1Y Performance:
+97.12%
1-Day Range:
$32.34
$34.41
1-Week Range:
$30.49
$34.41
52-Week Range:
$16.72
$34.41
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
32.80 | 2.29B | 0 | -195.21M | -176.19M | -3.1763 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-09-26 | Initiated | RBC Capital Mkts | Outperform |
| Oct-15-25 | Initiated | H.C. Wainwright | Buy |
| Oct-09-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-11-25 | Initiated | Guggenheim | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
Pharvaris NV (PHVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pharvaris (PHVS) CEO Modig sells 2,291 shares in planned Rule 10b5-1 trades - Stock Titan
Pharvaris NV (PHVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pharvaris NV (PHVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pharvaris NV (PHVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pharvaris NV (PHVS) Institutional Confidence - TradingKey
Pharvaris NV (PHVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pharvaris NV (PHVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Why (PHVS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Pharvaris (PHVS) CMO Lu Peng has 117 RSU shares withheld for taxes - Stock Titan
Pharvaris stock rating reiterated at Buy by H.C. Wainwright on safety data - Investing.com
PHVS Technical Analysis & Stock Price Forecast - Intellectia AI
Pharvaris (PHVS) CMO reports 109 shares withheld for RSU tax obligations - Stock Titan
PHVS (NASDAQ: PHVS) Rule 144 notice lists 2,291 RSUs; recent 10b5-1 sales noted - Stock Titan
Single capsule rapidly eased most HAE attacks in Pharvaris study - Stock Titan
Pharvaris NV (PHVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pharvaris N.V. (PHVS) Presents at World Orphan Drug Congress (WODC) USA 2026Slideshow - Seeking Alpha
Pharvaris (PHVS) Shows Modest Gains After Recent Pullback, Testing Key ResistanceSystematic Flow - newsline.com
Saturn V Capital Management LP's Pharvaris NV(PHVS) Holding History - GuruFocus
Does Pharvaris (PHVS) have the potential to rally 59.93% as Wall Street analysts expect? - MSN
Pharvaris Sets June 26, 2026 AGM as Late-Stage Angioedema Programs Advance - TipRanks
Pharvaris (Nasdaq: PHVS) details AGM plans and NDA timeline for HAE therapy - Stock Titan
Shareholders of Pharvaris to vote at June 26 annual meeting - Stock Titan
Why Pharvaris (PHVS) Is Up 8.6% After Expanding Deucrictibant HAE Data And Regulatory Plans - Sahm
Pharvaris N.V. (PHVS) Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress in HAE Pipeline - newsline.com
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000 - AOL.com
Insider Sell: Anna Nijdam Sells Shares of Pharvaris NV (PHVS) - GuruFocus
Pharvaris (PHVS) accounting officer sells 2,670 common shares on market - Stock Titan
A Look At Pharvaris (PHVS) Valuation As Deucrictibant Data Advances Toward Key EAACI 2026 Catalyst - Sahm
Understanding Momentum Shifts in (PHVS) - Stock Traders Daily
Anna Nijdam reports sales of PHVS common shares (PHVS) - Stock Titan
PHVS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pharvaris N.V. (PHVS) Presents at The 2026 Eastern Allergy ConferenceSlideshow (NASDAQ:PHVS) 2026-05-30 - Seeking Alpha
Pharvaris (PHVS) Holds Near Resistance as Shares Edge Higher on Modest VolumeRetail Driven Moves - The Legal Advocate
Pharvaris Trades Flat as Investors Wait for June Data Update - Bez Kabli
Pharvaris (PHVS) Edges Higher Amid Tight Trading Range, Testing Resistance at $31.61Death Cross - The Legal Advocate
Hereditary angioedema oral drug data headed to European allergy congress - Stock Titan
Pharvaris (PHVS) director Monges sells 9,667 shares, updates ownership - Stock Titan
Pharvaris (PHVS) accounting officer exercises options, sells 7,330 shares - Stock Titan
Pharvaris (PHVS) CFO/CLO Nassif sells 10,000 shares, corrects ownership - Stock Titan
Oppenheimer maintains Pharvaris NV (PHVS) outperform recommendation - MSN
Avoiding Lag: Real-Time Signals in (PHVS) Movement - Stock Traders Daily
B of A Securities Upgrades Pharvaris N.V. (PHVS) - MSN
Anna Nijdam proposes sale of 5,501 PHVS shares via Morgan Stanley (PHVS) - Stock Titan
Pharvaris (PHVS) director sells 10,000 shares, exercises options under 10b5-1 - Stock Titan
Pharvaris (PHVS) CEO Berndt Modig updates direct and indirect share holdings - Stock Titan
[144] Pharvaris N.V. SEC Filing - Stock Titan
Pharvaris (PHVS) CEO Modig sells 2,292 shares under Rule 10b5-1 plan - Stock Titan
PHVS (NASDAQ) Form 144/A: brokered resale of 4,667 and 5,333 common shares - Stock Titan
Director Robert Glassman of Pharvaris (PHVS) sells 10,000 shares after exercising options - Stock Titan
Pharvaris (PHVS) technical ops chief sells 8,748 shares in open market - Stock Titan
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):